Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy.
about
Nonsteroidal Anti-Inflammatory Therapy: A Journey Toward Safety.Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain.Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy.
P2860
Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Naproxcinod shows significant ...... f Duchenne Muscular Dystrophy.
@ast
Naproxcinod shows significant ...... f Duchenne Muscular Dystrophy.
@en
type
label
Naproxcinod shows significant ...... f Duchenne Muscular Dystrophy.
@ast
Naproxcinod shows significant ...... f Duchenne Muscular Dystrophy.
@en
prefLabel
Naproxcinod shows significant ...... f Duchenne Muscular Dystrophy.
@ast
Naproxcinod shows significant ...... f Duchenne Muscular Dystrophy.
@en
P2093
P2860
P50
P1476
Naproxcinod shows significant ...... f Duchenne Muscular Dystrophy.
@en
P2093
Antonello Villa
Barbara Vergani
Daniela Miglietta
Ennio Ongini
Viviana Pisa
P2860
P2888
P356
10.1186/S13023-015-0311-0
P577
2015-08-22T00:00:00Z
P5875
P6179
1007112037